GCP AND MEDICAL DEVICES

Slides:



Advertisements
Similar presentations
Development Cycle of Medical Devices: A Path of Opportunities for Information Professionals Donna Gay Pharma & Health Tech Div, SLA 2007 Spring Meeting.
Advertisements

Sorenson Medical, West Jordan, Utah USA Medical Device Development Robert Hitchcock, Ph.D. Director of Engineering & Technology Development Sorenson Medical,
Regulatory Pathway for Platform Technologies
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
IRB Process & Medical Devices
Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological.
Capturing and Reporting Adverse Events in Clinical Research
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
Medical Device Submissions
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
University of Medicine and Dentistry of New Jersey John L. Ricci, Ph.D., Department of Orthopaedics History and Scope of Biomaterials J. L. Ricci, Ph.D.
Special Topics in IND Regulation
Medical Devices Approval Process
Donna M. Liewer FCLB Executive Director Understanding the FDA: Key Considerations for Regulatory Agencies.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Product Definition Chapter 4. What is a Medical Device? FDA: “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,
Presented by: George Howe Executive Vice President Business Development & OEM Accounts.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Device Research Presented by Marian Serge, R.N.. Goals Identify devices Recognize difference between significant risk (SR) and non- significant risk (NSR)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
1 Importation of Medical Devices FDA Chicago District O’Hare Import Resident Post August 26, 2010 Import Entry Review Team Tamara M. Qtami, CSO.
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
Medical Devices IRB Determination IRB Member Continuing Education.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Regulatory Decision Making D. Kathleen Wright, Reviewer Division of Microbiology Office of In Vitro Diagnostic Device Evaluation & Safety ( OIVD ) Food.
The Food and Drug Administration Allison Kotchman Victoria Gilbride.
Investigational Devices and Humanitarian Use Devices June 2007.
REGULATION OF MEDICAL DEVICES INNOVATION TUĞÇE YAŞAR
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
PD233: Design of Biomedical Devices and Systems (Lecture 2) Dr. Manish Arora CPDM, IISc Course Website:
Executive Director, Registrar Corp
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
The Food and Drug Administration
What Are the FDA Requirements for Submitting an IDE?
Guidance for review of studies involving HCT/Ps and IND Basics
Division of Cardiovascular Devices
Premarket Notification 510(k) process
Investigator of Record – Definition
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Adverse Event Reporting: Trials and Tribulations
Clinical Trials Medical Interventions
Overview of regulatory and compliance in software development for medical devices
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Device complications.
Clinical Trials.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
SERIOUS ADVERSE EVENTS REPORTING
Investigator of Record – Definition
Investigator of Record – Definition
Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Opening an IND: Investigator Perspective
Er. Ajai Basil Consultant, Healthcare Technologies (Medical devices)
Policy on Prompt Reporting
Presentation transcript:

GCP AND MEDICAL DEVICES DIA GCP/QA ALL SIAC CALL 23 OCT 2008 Maryrose Petrizzo, MS Manager, Clinical QA, Boston Scientific

WHAT IS A DEVICE? A device is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is– recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them,

WHAT IS A DEVICE? intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. FD&C Act Part II Sec. 201 (h)

DEVICE CLASS Class I devices are subject to the least regulatory control. They present minimal potential for harm to the user and are often simpler in design than Class II or Class III devices. Class I devices are subject to "General Controls" as are Class II and Class III devices. Examples: elastic bandages, exam gloves

DEVICE CLASS Class II devices are those for which general controls alone are insufficient to assure safety and effectiveness, and existing methods are available to provide such assurances. In addition to complying with general controls, Class II devices are also subject to special controls. Examples: powered wheelchairs, infusion pumps

DEVICE CLASS Class III is the most stringent regulatory category for devices. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls. support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. Examples: replacement heart valves, breast implants

GCP Similarities with Drug Trials Part 11 – Electronic Records and Signatures Part 50 – Protection of Human Subjects Part 54 – Financial Disclosure by Clinical Investigators Part 56 – Institutional Review Boards

Drugs vs. Devices Parts 312 vs. 812 Investigational New Drug Application vs. Investigational Device Exemptions NDA vs. Premarket Notification510(k), Premarket Approval, 510(k) – to show Substantial Equivalence and gain “clearance” most Class I and some Class II PMA – Significant Risk device that you want “approved” for market most Class III not SE

Differences from Drug Trials Terminology Drug studies are usually much larger than IDE studies, although post-market studies of devices can be large registry trials. Blinding is often not possible for devices Placebo control is often not possible Many device studies are not interventional Many device studies augment other therapies/procedures

Differences from Drug Trials 1572 vs. Investigator Agreement IA must be signed by all clinical investigators, including sub-I’s. Need CVs and FDs for all who sign.

Differences from Drug Trials Adverse Event Reporting – IND Safety Reports (312.64) An investigator shall promptly report to the sponsor any AE that may reasonably be regarded as caused by, or probably caused by, the drug. If the AE is alarming, the investigator shall report the AE immediately.

Differences from Drug Trials Medical Device Reporting (803.3) MDR events: An event that Sponsor becomes aware of that reasonably suggests that a device has or may have caused or contributed to a death or serious injury; or that one of their marketed devices: may have caused or contributed to a death or serious injury, or Has malfunctioned

Differences from Drug Trials Unanticipated Adverse Device Effects (812.150) An investigator shall report to the sponsor and the IRB a report of any UADE occurring during an investigation as soon as possible, but no later than 10 working days after the investigator first learns of the UADE.

MEDICAL DEVICE STUDY CHALLENGES GMP mentality Marketing Driven GCP and Post-market studies Combination Products Comparator studies to drugs or surgery Drug studies setting the bar high for GCP

FUTURE Medical Device clinical research continues to be evolving, fast-paced, and interesting arena for GCP/QA personnel Increasing number of medical device company representatives attending DIA events. Is there a need to create a GCP/QA working group ?

THANK YOU Contact Info Maryrose Petrizzo (302) 762-2244 petrizzm@bsci.com